Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) E. C. Smyth et al.   ANNALS OF ONCOLOGY

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report

(2014) Angelika Bezan et al.   BMC CANCER

The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study

(2014) M. M. Heiss et al.   CLINICAL CANCER RESEARCH

Optimal chemotherapy for advanced gastric cancer: is there a global consensus?

(2013) Florian Lordick et al.   Gastric Cancer

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

(2012) Fausto Petrelli et al.   Targeted Oncology

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial

(2011) Xiao-Jun Yang et al.   ANNALS OF SURGICAL ONCOLOGY

Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial

(2011) Michael A. Ströhlein et al.   ONKOLOGIE

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER